Pular para o conteúdo principal
Ranking Invest

URGN - UroGen Pharma Ltd.

Segmento: HealthcareUroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Análise Ranking Invest

Valor de Mercado
$ 1.66 Bi
IVR
-0.35Índice proprietário de comparação relativa: -0,35.
IVR2
-0.26Leitura proprietária complementar: -26%.
MLL
-0.26Leitura proprietária complementar: -26%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

-$ 132.40 Mi

Dívida Líquida

$ 120.87 Mi

L4T

-$ 97.64 Mi

MM4T

-64.27%

Indicadores Básicos

ROE

73.75%

Índices de Previsibilidade

Receita Líquida

E0.16

Lucro

B0.22

Margem

C0.33

Índices de Tendência

Receita Líquida

B9.74

Lucro

D-0.95

Margem

B5.38

Índices de Endividamento

DIV/PAT

-0.91

DIV/L4T

-1.24

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.